IR-Med Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Ran Ziskind
Chief executive officer
US$86.2k
Total compensation
| CEO salary percentage | 9.53% |
| CEO tenure | less than a year |
| CEO ownership | n/a |
| Management average tenure | 4.3yrs |
| Board average tenure | 4.4yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2024 | US$86k | US$8k | -US$2m |
Compensation vs Market: Ran's total compensation ($USD86.21K) is below average for companies of similar size in the US market ($USD679.45K).
Compensation vs Earnings: Insufficient data to compare Ran's compensation with company performance.
CEO
Ran Ziskind (55 yo)
less than a year
Tenure
US$86,205
Compensation
Mr. Ran Ziskind is Chief Executive Officer of IR-Med Inc. from September 1, 2024. Mr. Ziskind is a highly experienced high-tech innovator and company leader with two decades of expertise in launching, deve...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Chairman | 11.7yrs | no data | 11.96% $ 703.3k | |
| Chief Executive Officer | less than a year | US$86.21k | no data | |
| Co-Founder | 11.7yrs | US$122.32k | 10.91% $ 642.0k | |
| Chief Development Officer | 4.1yrs | US$163.86k | 0% $ 0 | |
| Co-Founder | 2.3yrs | no data | 10.91% $ 642.0k | |
| CFO, Treasurer & Secretary | 4.4yrs | no data | 0.21% $ 12.3k |
4.3yrs
Average Tenure
57yo
Average Age
Experienced Management: IRME's management team is considered experienced (4.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Chairman | 11.7yrs | no data | 11.96% $ 703.3k | |
| Co-Founder | 11.7yrs | US$122.32k | 10.91% $ 642.0k | |
| Co-Founder | 4.4yrs | no data | 10.91% $ 642.0k | |
| Director | 4.4yrs | no data | 0% $ 0 | |
| Member of Advisory Board | 1.7yrs | no data | no data | |
| Independent Director | no data | no data | no data | |
| Independent Director | 4.4yrs | US$25.43k | 0.50% $ 29.4k | |
| Director of IR-Med Ltd | 10.3yrs | no data | no data |
4.4yrs
Average Tenure
66yo
Average Age
Experienced Board: IRME's board of directors are considered experienced (4.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/13 09:03 |
| End of Day Share Price | 2025/05/13 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
IR-Med Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Thomas Kerr | Zacks Small-Cap Research |